Risks Associated With Statin Therapy
Top Cited Papers
- 19 December 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 114 (25) , 2788-2797
- https://doi.org/10.1161/circulationaha.106.624890
Abstract
Background— Although statins reduce the risk of cardiovascular events, concerns about adverse effects may deter physicians from prescribing these agents. We performed a systematic overview of randomized statin trials to quantify the risks of musculoskeletal, renal, and hepatic complications associated with therapy. Methods and Results— Major statin trials were identified by electronic search of the MEDLINE database from 1966 to December 2005. We included English language reports of adults with documented hyperlipidemia; double-blind, random allocation of ≥100 patients to statin monotherapy versus placebo; and reports of myalgia, creatine kinase elevations, rhabdomyolysis, transaminase elevations, and discontinuation due to adverse events. Among 74 102 subjects enrolled in 35 trials (follow-up range, 1 to 65 months), statin therapy (excluding cerivastatin) did not result in significant absolute increases in risks of myalgias (risk difference/1000 patients [RD], 2.7; 95% CI, −3.2 to 8.7), creatine kinase el...Keywords
This publication has 60 references indexed in Scilit:
- The cerivastatin withdrawal crisis: a “post-mortem” analysisHealth Policy, 2004
- Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled TrialMayo Clinic Proceedings, 2004
- Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per dayThe American Journal of Cardiology, 2003
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunctionThe American Journal of Cardiology, 1998
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A ReappraisalDrug Safety, 1996
- Dose-Response of Simvastatin in Primary HypercholesterolemiaJournal of Cardiovascular Pharmacology, 1994
- Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factorsThe American Journal of Cardiology, 1993
- Efficacy and safety of pravastatin in patients with primary hypercholesterolemiaAtherosclerosis, 1990